2. Search Result
Search Result
Results for "

LDHA

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Natural
Products

4

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139319
    LDHA-IN-3
    1 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer .
    LDHA-IN-3
  • HY-18968
    LDHA-IN-4

    		Lactate Dehydrogenase Cancer
    AZ-33 is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM .
    LDHA-IN-4
  • HY-146977
    LDHA/PDKs-IN-1

    		PDK-1 Cancer
    LDHA/PDKs-IN-1 (compound 20e) is a potent and dual inhibitor of PDKs and LDHA with IC50s of 0.8 and 0.15 μM, respectively. LDHA/PDKs-IN-1 reduces A549 cell proliferation with an EC50 of 13.2 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-1 has the potential for the research of cancer diseases .
    LDHA/PDKs-IN-1
  • HY-146978
    LDHA/PDKs-IN-2

    		PDK-1 Cancer
    LDHA/PDKs-IN-2 (compound 20k) is a potent and dual inhibitor of PDKs and LDHA with IC50s of 1.6 and 0.7 μM, respectively. LDHA/PDKs-IN-2 reduces A549 cell proliferation with an EC50 of 15.7 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-2 has the potential for the research of cancer diseases .
    LDHA/PDKs-IN-2
  • HY-162627
    LDHA-IN-6

    		Lactate Dehydrogenase Cancer
    LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC50 of 46 nM. LDHA-IN-6 has antitumor activity .
    LDHA-IN-6
  • HY-169060
    LDHA-IN-8

    		Lactate Dehydrogenase Cancer
    LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits LDHA catalysis of pyruvate in a dose-dependent manner (EC50 value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .
    LDHA-IN-8
  • HY-115875
    LDHA-IN-5

    		Lactate Dehydrogenase Metabolic Disease
    LDHA-IN-5 is a novel, potent, dual GO/LDHA inhibitor for primary hyperoxaluria.
    LDHA-IN-5
  • HY-168733
    LDHA-IN-9

    		Lactate Dehydrogenase Apoptosis Cancer
    LDHA-IN-9 (Compound 1g) is an inhibitor for LDH-A with an IC50 of 25 nM. LDHA-IN-9 inhibits the proliferation of DLD-1 cell (GI50 of 27 μM) through apoptosis induction. LDHA-IN-9 exhibits antitumor activity in mouse model without significant toxicity (25 mg/kg) .
    LDHA-IN-9
  • HY-162629
    LDHA-IN-7

    		Lactate Dehydrogenase Cancer
    LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC50s of 72 nM and 1.2 Μm, respectively .
    LDHA-IN-7
  • HY-RS07571
    LDHA Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LDHA Human Pre-designed siRNA Set A contains three designed siRNAs for LDHA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LDHA Human Pre-designed siRNA Set A
    LDHA Human Pre-designed siRNA Set A
  • HY-16214
    FX-11
    15+ Cited Publications

    LDHA Inhibitor FX11

    		 Lactate Dehydrogenase Apoptosis Reactive Oxygen Species Cancer
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
    FX-11
  • HY-100742
    GNE-140 racemate
    5+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .
    GNE-140 racemate
  • HY-152261
    MS6105

    		PROTACs Cancer
    MS6105 is an LDH protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity . MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MS6105
  • HY-100742A
    (R)-GNE-140
    10+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
    (R)-GNE-140
  • HY-100742B
    (S)-GNE-140

    		Lactate Dehydrogenase Cancer
    (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).
    (S)-GNE-140
  • HY-100681
    GSK2837808A
    Maximum Cited Publications
    25 Publications Verification

    		 Lactate Dehydrogenase Cancer
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A
  • HY-111108
    LDH-IN-1
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
    LDH-IN-1
  • HY-147361
    LDCA

    		Apoptosis Lactate Dehydrogenase Cancer
    LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .
    LDCA
  • HY-124309
    NHI-2

    		Lactate Dehydrogenase Cancer
    NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease .
    NHI-2
  • HY-W013032
    Oxamic acid
    5+ Cited Publications

    Oxamidic acid

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
    Oxamic acid
  • HY-W013032A
    Oxamic acid sodium
    5+ Cited Publications

    Sodium oxamate

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
    Oxamic acid sodium
  • HY-156683
    CHK-336

    		Lactate Dehydrogenase Metabolic Disease
    CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM) that inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .
    CHK-336
  • HY-W040118
    Galloflavin
    5 Publications Verification

    		 Lactate Dehydrogenase Cancer
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .
    Galloflavin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: